Home | Products/Services | Newsstand | Join Now | Partner | Support
  Member Login
    User:  
Pass:  
  Forgot password?
   Member Benefits
   Small-Tech Vendors
   Information Portal

 
BioSante Pharmaceuticals to Present At BIO Emerging Company Investor Forum

LINCOLNSHIRE, Ill.-Oct. 13, 2004- BioSante Pharmaceuticals, Inc. (AMEX:BPA) announced today that Phillip Donenberg, chief financial officer, will be presenting at the BIO Emerging Company Investor Forum in San Francisco at 9:30 a.m. PDT (12:30 p.m. EDT) on October 15, 2004.

Mr. Donenberg will discuss the company's product pipeline of hormone therapy products, including positive data recently reported on LibiGel(TM) transdermal testosterone gel for the treatment of female sexual dysfunction, as well as its calcium phosphate (CAP) nanotechnology under development for drug delivery and vaccines. A Web cast of the presentation will be available on BioSante's Web site at http://www.biosantepharma.com/investors/events.htm approximately one hour after the conclusion of the presentation, and will be archived for one year.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The transdermal gel formulations used in the hormone therapy products are licensed from Antares Pharma, Inc. (Amex:AIS). The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales.

The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com

(source: BUSINESS WIRE)
 
1/31/2005
SST and Nanotech Corporation Sign Licensing Agreement for Advanced Flash Memory Solutions
1/31/2005
Biophan Announces Issuance of Two New Patents in MRI Compatibility, Expands Lead in Intellectual Property
1/31/2005
Starpharma ADRs Added to Nanosphere List of Leading Nanotechnology Stocks for 2005
8/16/2004
JMAR Technologies Reports Its Second Quarter Results; Proceeds from $8 Million Financing Being Used to Expand Product Development Act
8/16/2004
BioSante Pharmaceuticals Announces Second Quarter Financial Results
8/16/2004
Lux Research Releases 'The Nanotech Report 2004' Key Findings

Advertise With Us

Featured Company

Norcada

Norcada is a MEMS product and microfabrication technology development company based in Edmonton, Canada. Norcada specializes in contract R&D and prototype...

More...  
 .

Featured Product

Optics

Across applications, EFAB is the ideal technology for building MEMS devices for optical products including 2-D and 3-D micromirror devices, optical...

More...  
 .

   © 2002 - 2010 Dynano Incorporated. All Rights Reserved.   Terms of Use & Privacy Policy